bpc-157 synthagen 500MCG Capsules synthagen laboratories bpc 157 review

In another phase 2 trial of obese patients with type 2 diabetes, the combination of cagrilintide 2.4 mg/week and the GLP-1R semaglutide 2.4 mg/week (referred to as CagriSema) was compared with each drug alone

Common side effects (may affect up to 1 in 10 people): * Pain, redness, or swelling at the injection site * Nausea * Headache Uncommon side effects (may affect up to 1 in 100 people): * Diarrhea * Dizziness * Allergic reactions such as skin rash, itching, or hives Rare side effects (may affect up to 1 in 1,000 people): * Severe allergic reaction (anaphylaxis) with symptoms like difficulty breathing, swelling of the face or throat, and a drop in blood pressure

Reduce frequency to 2 to 3 injections weekly at the same 1 to 2mg dose per injection

Each component has been independently studied for its proposed role in appetite regulation, glucose control, and gastric motility